Details of the Drug

General Information of Drug (ID: DMBZ27L)

Drug Name
Favipiravir
Synonyms AIDS121660; Favipiravir (JAN/INN); 3-bromo-5-hydroxy-4-methyl-2,6-dinitro-benzoic Acid; T705
Indication
Disease Entry ICD 11 Status REF
Influenza virus infection 1E30-1E32 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 157.1
Logarithm of the Partition Coefficient (xlogp) -0.6
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 51.5 mg/L [3]
Bioavailability
The bioavailability of drug is 97.6% [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 5.5 hours [4]
Metabolism
The drug is metabolized via the aldehyde oxidase and to a lesser extent by xanthine oxidase to the inactive metabolite T705M1 [5]
Vd
The volume of distribution (Vd) of drug is 15-20 L [6]
Chemical Identifiers
Formula
C5H4FN3O2
IUPAC Name
5-fluoro-2-oxo-1H-pyrazine-3-carboxamide
Canonical SMILES
C1=C(N=C(C(=O)N1)C(=O)N)F
InChI
InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
InChIKey
ZCGNOVWYSGBHAU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
492405
ChEBI ID
CHEBI:134722
CAS Number
259793-96-9
DrugBank ID
DB12466
TTD ID
D0Y4LX
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mycobacterium RNA polymerase (MycB RNAP) TT79JGK RPOA_MYCTU ; RPOB_MYCTU ; RPOC_MYCTU ; RPOZ_MYCTU Modulator [7]
COVID-19 RNA-directed RNA polymerase (RdRp) TTV1095 R1AB_SARS2 (4393-5324) Inhibitor [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 ClinicalTrials.gov (NCT04336904) Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
3 Pharmaceuticals and Medical Devices Agency: Avigan (favipiravir) Review Report
4 Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019 Apr;32(2):176-186. doi: 10.1097/QCO.0000000000000532.
5 Rosenberry TL, Sonoda LK, Dekat SE, Cusack B, Johnson JL: Analysis of the reaction of carbachol with acetylcholinesterase using thioflavin T as a coupled fluorescence reporter. Biochemistry. 2008 Dec 9;47(49):13056-63. doi: 10.1021/bi8015197.
6 Nguyen TH, Guedj J, Anglaret X, Laouenan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentre F: Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389. doi: 10.1371/journal.pntd.0005389. eCollection 2017 Feb.
7 Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res.2013 Nov;100(2):446-54.
8 Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. Posted April 15, 2020.